X4 Pharmaceuticals share price logo

X4 Pharmaceuticals

NASDAQ: XFOR

Small Cap

$3.21

+0.01

(+0.31%)

Live

as on

X4 Pharmaceuticals Stock Performance

as on October 24, 2026 at 6:22 am IST

  • Day's Low

    Day's High

    $3.02
    $3.23
    downward going graph

    5.92%

    Downside

    0.62%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.43
    $4.83
    downward going graph

    24.30%

    Downside

    50.47%

    Upside

    downward going graph

X4 Pharmaceuticals share price movements today

Previous Close
$3.20
Open
$3.15
Volume
383.7K
Market Cap
$298.4M
Day's Low - High
$3.02 - $3.23
52 Week Low - High
$2.43 - $4.83

X4 Pharmaceuticals Historical Returns

1 Month Return
+ 2.89 %
3 Month Return
-19.8 %
1 Year Return
+ 3.56 %
3 Year Return
-87.02 %
5 Year Return
-97.63 %

X4 Pharmaceuticals Stock Fundamentals & Key Indicators

Check X4 Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$298.4M

EPS (TTM)

-1.2

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.51

Industry PE ratio

-7.12

PEG Ratio

-0.01

EBITDA

-79.8M

Revenue (TTM)

15.8M

Profit Margin

81.22%

Return On Equity TTM

-63.05%

X4 Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of X4 Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$298.4M-97.63%-2.5181.22%0.00%
Neutral$98.1B-37.95%-30.80-12.57%0.00%
StrongBuy$44.0BNA27.4787.82%0.00%
StrongBuy$132.9B191.61%30.2886.04%0.00%
Buy$83.1B43.11%19.2484.86%0.46%

Stock Returns calculator for X4 Pharmaceuticals Stock including INR - Dollar returns

The X4 Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

X4 Pharmaceuticals investment value today

Current value as on today

₹1,12,358

Returns

₹12,358

(+12.36%)

Returns from X4 Pharmaceuticals Stock

₹3,883 (+3.88%)

Dollar Impact

₹8,475 (+8.47%)

Analyst Recommendation on X4 Pharmaceuticals Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for X4 Pharmaceuticals. Average target price of $11.6

X4 Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on X4 Pharmaceuticals.

What analysts predicted

72.33%UPSIDE

Target Price

$11.6

Current Price

$3.21

Analyzed by

2 Analysts

High

$12

Target

$11.60

Low

$11

X4 Pharmaceuticals target price $11.6, a slight upside of 72.33% compared to current price of $3.21. According to 2 analysts rating.

Indian Investors' Interest in X4 Pharmaceuticals Stock

Search interest for X4 Pharmaceuticals Stock has increased by 4% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:4% versus previous 30 day period

X4 Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
0
1
28
1
1
2
2
8
Gross Profit
0
0
0
1
23
1
1
2
2
7
Operating Income
-37
-33
-34
-35
-9
-26
-27
-23
-20
-16
EBITDA
-49
93
-33
-36
2
-23
-27
-21
-17
-13
Interest Expense
1
2
2
2
2
2
2
2
2
2
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-51
90
-36
-39
0
-25
-29
-23
-20
-16
Income Tax Expense
0
0
0
0
0
0
0
-
-
0
Net Income
-51
90
-36
-39
0
-25
-29
-23
-20
-16
Net Profit Margin
0.00%
52.40%
45.18%
78.94%
82.63%
74.96%
78.81%
84.93%
77.92%
81.64%

X4 Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
3
-
-
-
2
35
Gross Profit
0
0
0
1
-1
-
-
1
28
Operating Income
-36
-29
-46
-59
-75
-87
-107
-36
-86
EBITDA
-35
-28
-46
-58
-83
-89
-94
-27
-69
Interest Expense
2
0
2
2
3
3
5
8
8
Depreciation
0
0
0
1
1
0
0
0
1
Income Before Tax
-33
-33
-52
-61
-88
-93
-101
-37
-79
Income Tax Expense
-
-
-
0
0
0
0
0
0
Net Income
-33
-33
-52
-62
-88
-93
-101
-37
-79
Net Profit Margin
0.00%
97.06%
0.00%
100.00%
0.00%
0.00%
0.00%
68.83%
82.18%

X4 Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-51
90
-36
-39
0
-25
-29
-23
-20
-16
Operating Cash Flow
-33
-30
-34
-32
-12
-29
-27
-15
-19
-20
Investing Cash Flow
-5
96
-15
-8
-3
23
-28
16
19
-1
Financing Cash Flow
-
20
-
0
-
5
86
146
0
0
Change in Cash
-38
86
-49
-41
-15
-1
30
147
0
-21

X4 Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-33
-33
-52
-62
-88
-93
-101
-37
-79
Operating Cash Flow
-27
-25
-48
-58
-70
-77
-96
-130
-85
Investing Cash Flow
0
-
27
-1
0
0
-14
66
8
Financing Cash Flow
101
6
140
12
74
117
88
20
238
Change in Cash
73
-68
118
-47
2
39
-22
-43
161

Global Institutional Holdings in X4 Pharmaceuticals

Check out the Institutions with significant holdings in X4 Pharmaceuticals.

Funds
Holdings
Joseph Edelman
8.00%
Fidelity Securities Fund
5.12%
Vanguard
4.08%
VANGUARD INDEX FUNDS
3.44%
iShares
3.17%

X4 Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 09 September

    Wed, 04:05 PM

    -

    X4 Pharmaceuticals outlines mavorixafor strategy, highlighting leadership changes, funding, and pivotal Phase 3 study in chronic neutropenia.

    Wed, 04:30 PM

    -

    X4 Pharmaceuticals to participate in Wells Fargo Healthcare Conference on September 10, 2026.

Insights on X4 Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, XFOR stock has moved up by 23.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 671.9% return, outperforming this stock by 668.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 157.7% return, outperforming this stock by 244.7%

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
OrganisationX4 Pharmaceuticals
Headquarters61 North Beacon Street, Boston, MA, 02134, US
IndustryBiotechnology
CEOAdam R. Craig

Key Management of X4 Pharmaceuticals

Name

Title

Dr. Adam R. Craig M.B.A., M.D., Ph.D.

Executive Chair

Mr. John P. Volpone M.B.A.

President & COO

Mr. David H. Kirske

CFO, Treasurer & Corporate Secretary

Dr. Richard Peters M.D., Ph.D.

Founder

Dr. Renato T. Skerlj Ph.D.

Founder

Dr. Keith T. Flaherty M.D.

Founder & Member of Corporate Advisory Board

FAQs

What is X4 Pharmaceuticals share price today?

X4 Pharmaceuticals share price today is $3.21 as on . X4 Pharmaceuticals share today touched a day high of $3.23 and a low of $3.02.

What is the 52 week high and 52 week low for X4 Pharmaceuticals share?

X4 Pharmaceuticals share touched a 52 week high of $4.83 on and a 52 week low of $2.43 on . X4 Pharmaceuticals stock price today i.e. is trending at $3.21,which is 33.54% down from its 52 week high and 32.10% up from its 52 week low.

What is X4 Pharmaceuticals's market capitalisation today?

X4 Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in X4 Pharmaceuticals Stock (XFOR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for X4 Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy X4 Pharmaceuticals Stock (XFOR) from India?

Indian investors can start investing in X4 Pharmaceuticals (XFOR) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in X4 Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on X4 Pharmaceuticals share’s latest price of $3.21 as on October 24, 2026 at 12:52 am IST, you will get 3.1153 shares of X4 Pharmaceuticals. Learn more about fractional shares .

What are the returns that X4 Pharmaceuticals has given to Indian investors in the last 5 years?

X4 Pharmaceuticals stock has given -97.63% share price returns and 26.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?